1)Nitschke L, Tsubata T. Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends Immunol. 2004; 25: 543-50
|
|
|
2)O'Keefe TL, Williams GT, Batista FD, et al. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med. 1999; 189: 1307-13
|
|
|
3)Qu WM, Miyazaki T, Terada M, et al. Genetic dissection of vasculitis in MRL/lpr lupus mice: a novel susceptibility locus involving the CD72c allele. Eur J Immunol. 2000; 30: 2027-37
|
|
|
4)Hitomi Y, Tsuchiya N, Kawasaki A, et al. CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B. Hum Mol Genet. 2004; 13: 2907-17
|
|
|
5)Mary C, Laporte C, Parzy D, et al. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol. 2000; 165: 2987-96
|
|
|
6)Nitschke L, Lajaunias F, Moll T, et al. Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-prone mice affects ligand binding. Int Immunol. 2006; 18: 59-68
|
|
|
7)Hokazono Y, Adachi T, Wabl M, et al. Inhibitory coreceptors activated by antigens but not by anti-Ig heavy chain antibodies install requirement of costimulation through CD40 for survival and proliferation of B cells. J Immunol. 2003; 171: 1835-43
|
|
|
8)Garside P, Ingulli E, Merica RR, et al. Visualization of specific B and T lymphocyte interactions in the lymph node. Science. 1998; 281: 96-9
|
|
|
9)Wakabayashi C, Adachi T, Wienands J, et al. A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science. 2002; 298: 2392-5
|
|
|
10)Waisman A, Kraus M, Seagal J, et al. IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig alpha/beta. J Exp Med. 2007; 204: 747-58
|
|
|
11)Horikawa K, Martin SW, Pogue SL, et al. Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J Exp Med. 2007; 204: 759-69
|
|
|
12)Hennet T, Chui D, Paulson JC, et al. Immune regulation by the ST6Gal sialyltransferase. Pro Natl Acad Sci USA. 1998; 95: 4504-9
|
|
|
13)Ghosh S, Bandulet C, Nitschke L. Regulation of B cell development and B cell signalling by CD22 and its ligands alpha2, 6-linked sialic acids. Int Immunol. 2006; 18: 603-11
|
|
|
14)Collins BE, Smith BA, Bengtson P, et al. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nature Immunology. 2006; 7: 199-206
|
|
|
15)Lanoue A, Batista FD, Stewart M, et al. Interaction of CD22 with alpha2, 6-linked sialoglycoconjugates: innate recognition of self to dampen B cell autoreactivity? Eur J Immunol. 2002; 32: 348-55
|
|
|
16)Yu J, Sawada T, Adachi T, et al. Synthetic glycan ligand excludes CD22 from antigen receptor-containing lipid rafts. Biochem Biophys Res Commun. 2007; 360: 759-64
|
|
|
17)Kelm S, Gerlach J, Brossmer R, et al. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med. 2002; 195: 1207-13
|
|
|
18)Irie A, Koyama S, Kozutsumi Y, et al. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem. 1998; 273: 15866-71
|
|
|
19)Kawano T, Koyama S, Takematsu H, et al. Molecular cloning of cytidine monophospho-N-acetylneuraminic acid hydroxylase. Regulation of species- and tissue-specific expression of N- glycolylneuraminic acid. J Biol Chem. 1995; 270: 16458-63
|
|
|
20)Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007; 7: 255-66
|
|
|
21)Naito Y, Takematsu H, Koyama S, et al. Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol Cell Biol. 2007; 27: 3008-22
|
|
|